Skip to main content
. 2022 Apr 26;13:831194. doi: 10.3389/fimmu.2022.831194

Table 1.

General characteristics of COVID-119 patients classified by pulmonary fibrosis index.

All patients COVID-19 patients p-value
FI ≤ 0.0567 FI > 0.0567
Number 12 6 6
Collection days since disease onset (days) 13.0 (5.5–18.5) 13.0 (8.5–19.5) 14 (2.75–23.5) 0.94
Male (%) 8 (66.7%) 4 (66.7%) 4 (66.7%) 1.00
Age (years) 63 (47–70) 49 (44–69) 70 (61–72) 0.067
Hypertension (%) 2 (16.7%) 1 (16.7%) 1 (16.7%) 1.00
Diabetes (%) 0 (0%) 0 (0.0%) 0 (0.0%) 1.00
Cardiovascular disease (%) 3 (25.0%) 1 (16.7%) 2 (33.0%) 1.00
Body temperature on admission (°C) 37.1 (36.6–38.0) 37.2 (36.8–38.0) 37.1 (36.5–38.1) 0.97
SpO2 (%) 96.9 (93.3–99.4) 98.3 (93.3–99.5) 95.5 (92.0–99.3) 0.82
Red blood cell count (×1012/L) 4.34 (4.18–4.92) 4.49 (3.93–4.95) 4.30 (4.21–4.96) 1.00
White cell count (×109/L) 6.69 (4.58–7.34) 5.84 (4.32–7.90) 6.88 (4.90–11.53) 0.59
Neutrophil percentage (%) 71.9 (63.5–80.3) 66.8 (57.3–78.6) 76.4 (67.1–83.2) 0.29
Lymphocyte percentage (%) 19.9 (12.6–24.6) 21.8 (13.1–29.4) 16.7 (10.5–24.6) 0.24
Monocyte percentage (%) 5.5 (5.0–7.0) 5.9 (5.3–8.3) 5.1 (3.2–6.7) 0.24
Platelet count (×109/L) 189 (125–283) 203 (169–348) 140 (107–257) 0.31
Serum creatinine (μmol/L) 63 (47–76) 73 (45–78) 54 (47–75) 0.47
Alanine aminotransferase (U/L) 35 (28–79) 30 (28–83) 42 (26–78) 1.00
Aspartate aminotransferase (U/L) 39 (24–75) 26 (20–83) 53 (32–77) 0.39
Total bilirubin (μmol/L) 8.9 (6.7–16.1) 7.3 (5.5–8.6) 15.6 (11.9–23.4) 0.015
Creatine kinase (U/L) 68 (55–96) 68.5 (52.0–85.3) 65.0 (48.8–230.0) 0.97
Myoglobin (ng/ml) 63 (45–133) 58 (40–67) 108 (42–285) 0.39
C-reactive protein (ng/ml) 35.9 (14.0–50.7) 19.7 (7.8–41.2) 44.2 (30.5–55.8) 0.093

FI, pulmonary fibrosis index; computed by AI-assisted CT imaging. Data are expressed as median with interquartile range (IQR). Continuous data were compared by the Student’s t-test or Mann–Whitney test. Categorical data were assessed using Fisher exact test.